JP2004529915A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529915A5
JP2004529915A5 JP2002578975A JP2002578975A JP2004529915A5 JP 2004529915 A5 JP2004529915 A5 JP 2004529915A5 JP 2002578975 A JP2002578975 A JP 2002578975A JP 2002578975 A JP2002578975 A JP 2002578975A JP 2004529915 A5 JP2004529915 A5 JP 2004529915A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
glucose
composition according
glucose reabsorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002578975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529915A (ja
JP4590159B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/010538 external-priority patent/WO2002080936A1/en
Publication of JP2004529915A publication Critical patent/JP2004529915A/ja
Publication of JP2004529915A5 publication Critical patent/JP2004529915A5/ja
Application granted granted Critical
Publication of JP4590159B2 publication Critical patent/JP4590159B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002578975A 2001-04-04 2002-04-03 グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法 Expired - Fee Related JP4590159B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28142901P 2001-04-04 2001-04-04
PCT/US2002/010538 WO2002080936A1 (en) 2001-04-04 2002-04-03 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Publications (3)

Publication Number Publication Date
JP2004529915A JP2004529915A (ja) 2004-09-30
JP2004529915A5 true JP2004529915A5 (https=) 2005-12-22
JP4590159B2 JP4590159B2 (ja) 2010-12-01

Family

ID=23077253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578975A Expired - Fee Related JP4590159B2 (ja) 2001-04-04 2002-04-03 グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法

Country Status (11)

Country Link
US (3) US20030045553A1 (https=)
EP (2) EP1381361B1 (https=)
JP (1) JP4590159B2 (https=)
CN (1) CN100577175C (https=)
AT (1) ATE423559T1 (https=)
CA (1) CA2442917C (https=)
DE (1) DE60231295D1 (https=)
ES (1) ES2321815T3 (https=)
MY (1) MY180762A (https=)
TW (1) TWI330084B (https=)
WO (1) WO2002080936A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US20090162342A1 (en) * 2001-06-07 2009-06-25 Sanomune Inc. Therapeutic uses of glandular kallikrein
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
KR20060105431A (ko) * 2003-06-27 2006-10-11 닥터 레디스 리서치 파운데이션 발라글리타존 및 당뇨병치료제 화합물을 포함하는 조성물
EP1662906A1 (en) * 2003-09-23 2006-06-07 DSM IP Assets B.V. Compositions for the treatment and prevention of diabetes mellitus
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20080274193A1 (en) * 2004-01-23 2008-11-06 Japan Science And Technology Agency Retinoic Acid-Containing Antidiabetic Agent
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
KR20070011379A (ko) 2004-03-17 2007-01-24 라스 미카엘 라르센 시각 사이클 억제에 의한 망막증의 예방
EP1782828B1 (en) * 2004-07-21 2016-06-29 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
US7767682B2 (en) * 2005-03-03 2010-08-03 Glaxosmithkline Llc Medicaments
US20080280955A1 (en) * 2005-09-30 2008-11-13 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US8666671B2 (en) * 2007-07-05 2014-03-04 Enhanced Pharmaceuticals, Inc. Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
ES2541141T3 (es) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
EP2419097B1 (en) * 2009-04-16 2013-09-25 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
US20120115912A1 (en) * 2009-07-10 2012-05-10 Landreth Gary E Rxr agonist compounds and methods
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2667854T3 (es) * 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
US9451987B2 (en) 2011-11-16 2016-09-27 K2M, Inc. System and method for spinal correction
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CN102727477B (zh) * 2012-06-14 2014-07-16 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治糖尿病药物中的应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN111511402A (zh) * 2017-12-28 2020-08-07 国立大学法人福井大学 白内障的预防剂及/或治疗剂、用于预防及/或治疗白内障的医药组合物、ppar活化剂的用于制造它们的用途、以及滴眼剂
CN111437393B (zh) * 2020-04-30 2021-03-02 深圳微芯生物科技股份有限公司 用于糖尿病及其并发症治疗的联合用药及其药物组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH0253573A (ja) * 1988-08-11 1990-02-22 Nippon Riki Kk ラチェットレンチの製造法
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JP2762903B2 (ja) 1992-11-12 1998-06-11 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
JP2795162B2 (ja) 1993-02-18 1998-09-10 田辺製薬株式会社 ジヒドロカルコン誘導体及びその製法
JP2906978B2 (ja) 1993-02-25 1999-06-21 田辺製薬株式会社 血糖降下剤
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
ATE259227T1 (de) 1995-09-18 2004-02-15 Ligand Pharm Inc Behandlung von niddm (nichtinsulinabhängige diabetes mellitus) mit rxr agonisten
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance
AU719726B2 (en) * 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4100734B2 (ja) 1997-04-30 2008-06-11 Ｓａｂｉｃイノベーティブプラスチックスジャパン合同会社 熱可塑性樹脂組成物
AU8799998A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
US6337426B1 (en) 1998-11-23 2002-01-08 Nalco/Exxon Energy Chemicals, L.P. Antifoulant compositions and processes
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4649600A (en) 1999-04-22 2000-11-10 Joel F. Habener Bridge-1, a transcription factor
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
PE20010580A1 (es) 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2001192375A (ja) * 1999-10-29 2001-07-17 Takeda Chem Ind Ltd オキシイミノアルカン酸誘導体の結晶
TW558554B (en) 1999-10-29 2003-10-21 Takeda Chemical Industries Ltd Crystals of oxyiminoalkanoic acid derivative
HK1045991B (en) * 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
MXPA03003870A (es) 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Similar Documents

Publication Publication Date Title
JP2004529915A5 (https=)
JP2004529914A5 (https=)
CA2442917A1 (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
EP1730131B1 (de) Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5596799B2 (ja) カナグリフロジン含有錠剤
DE602004008100T2 (de) 4-biarylyl-1-phenylazetidin-2-one
JP2009506094A5 (https=)
RU2593499C2 (ru) Лекарственная форма левокарримицина, способ его получения и использования
CA2658116A1 (en) 1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors
JP2008524162A (ja) グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
DE102007035334A1 (de) Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
CA2534022A1 (en) Di-aryl glycoside derivatives and their use as sglt inhibitors
CA2443325A1 (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
JP2009535378A5 (https=)
CN1483039A (zh) 作为降血胆甾醇剂的糖取代的2-氮杂环丁烷酮
RU2647236C1 (ru) Левоизовалерилспирамицин ii, препараты, способ приготовления и употребления
EP2102225A4 (en) ALPHA-GALACTOSYL CERAMIDE DERIVATIVES, PHARMACEUTICALALLY SALTS THEREOF, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR IMMUNADJUVANS CONTAINING THEM AS AN ACTIVE SUBSTANCE
MX2023012835A (es) Composicion farmaceutica que comprende un agonista de gpr40 y un inhibidor de sglt-2.
CN102321019A (zh) 喹啉化合物的晶形及其生产方法
JP2004529172A5 (https=)
CN1408703A (zh) 具有β2－受体兴奋作用的新型苯乙醇胺类化合物及其制法
CN1968696A (zh) 用于治疗和控制肺高血压的包含沙利度胺的组合物以及其使用方法
EP1727798B1 (de) Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
CN1225096A (zh) 溴代台勾霉素化合物
CN105820163B (zh) 取代的1,3-杂唑类化合物、其制备方法、包含其的药物组合物及用途